In-Depth Market Analysis On Hepatitis B - Pipeline Review, H2 2016
Hepatitis B - Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Hepatitis B (Infectious Disease) pipeline landscape.
Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus. Hepatitis B virus can cause an acute illness with symptoms that last several weeks, including yellowing of the skin and eyes (jaundice), dark urine, extreme fatigue, nausea, vomiting and abdominal pain. Risk factors include age, severe kidney disease, hemophilia, share needles during drug use and born to a hepatitis-b infected mother. Treatment includes antiviral drugs.
To access full report with TOC, please visit Hepatitis B - Pipeline Review, H2 2016
Report Highlights
This report provides comprehensive information on the therapeutics under development for Hepatitis B (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hepatitis B (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis B and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 3, 10, 24, 18, 3, 58, 33 and 3 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 3, 7 and 6 molecules, respectively.Hepatitis B.
Hepatitis B (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis B (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Hepatitis B (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis B (Infectious Disease)
- The pipeline guide reviews pipeline therapeutics for Hepatitis B (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis B (Infectious Disease)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hepatitis B (Infectious Disease).
- Formulate corrective measures for pipeline projects by understanding Hepatitis B (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hepatitis B (Infectious Disease).
- Formulate corrective measures for pipeline projects by understanding Hepatitis B (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
Abivax SA AiCuris GmbH & Co KG AIMM Therapeutics BV Akshaya Bio Inc Alnylam Pharmaceuticals Inc AlphaMab Co., Ltd Altimmune Inc Altravax Inc Amarna Therapeutics BV Arbutus Biopharma Corp Arcturus Therapeutics Inc Arrowhead Pharmaceuticals Inc Assembly Biosciences Inc Beijing Kawin Technology Share-Holding Co Ltd Beijing Minhai Biotechnology Co Ltd Benitec Biopharma Ltd Biogenomics Limited Biological E Ltd BioStar Pharmaceuticals Inc Bolder Biotechnology Inc BrightGene Bio-Medical Technology Co Ltd Bukwang PharmCo Ltd CaroGen Corp Celltrion Inc Chong Kun Dang Pharmaceutical Corp Chromis Therapeutics, Inc. ChronTech Pharma AB Cocrystal Pharma Inc ContraVir Pharmaceuticals Inc CyTuVax BV Dicerna Pharmaceuticals Inc Dong-A Socio Holdings Co Ltd Dynavax Technologies Corp Ensemble Therapeutics Corp eTheRNA Immunotherapies NV F. Hoffmann-La Roche Ltd GeneCure LLC GeoVax Labs Inc Gilead Sciences Inc GlaxoSmithKline Plc Green Cross Corp Hanmi Pharmaceuticals Co Ltd HEC Pharm Co., Ltd. Humabs BioMed SA Huons Co Ltd Ildong Pharmaceutical Co Ltd Immunotope Inc Indian Immunologicals Ltd Intellia Therapeutics Inc Ionis Pharmaceuticals Inc ISA Pharmaceuticals BV Jiangsu Hansoh Pharmaceutical Co Ltd Johnson & Johnson Kineta Inc Lakewood-Amedex Inc Leukocare AG LG Life Science LTD Ligand Pharmaceuticals Inc Mucosis BV MultiCell Technologies Inc Oncolys BioPharma Inc Panacea Biotec Ltd Pfenex Inc PharmaEssentia Corp Poxel SA Profarma Profectus BioSciences Inc Redx Pharma Plc REPLICor Inc Rodos BioTarget GmbH Samjin Pharmaceutical Co Ltd Sanofi Pasteur SA Shantha Biotechnics Ltd Sinovac Biotech Ltd Spring Bank Pharmaceuticals Inc Staidson (Beijing) Biopharmaceuticals Co., Ltd. TCM Biotech International Corp TetraLogic Pharmaceuticals TGV-Laboratories Theravectys SA Tomegavax Inc Transgene SA Vaxine Pty Ltd VBI Vaccines Inc Viriom Ltd VLP Biotech Inc Zydus Cadila Healthcare Ltd
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###
posted by Reportstack @ 23:32
0 Comments
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home